Fosun Pharma grants share options and restricted shares to employees

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. has announced the first grant under its 2025 A Share Option Scheme and H Share RSU Scheme. On November 4, 2025, the board approved the grant of 4,535,100 A Share Options to 195 A Share Option participants at an exercise price of RMB27.93 per share. These grants represent approximately 0.1698% of the company's total A Shares in issue.

Concurrently, under the 2025 H Share RSU Scheme, 10,589,500 H Share RSUs were granted to 195 eligible employees, including executive directors and the chief executive. The H Share RSUs, granted on November 4, 2025, correspond to an equivalent number of Restricted H Shares. The closing price of H Shares on the grant date was HK$22.62 per H Share.

Individual H Share RSU grants ranged from 50,900 RSUs for Ms. Yan Jia to 953,500 RSUs for Mr. Chen, the chairman. Following these grants, 43,507,650 H Shares remain available for future grants under the H Share Scheme Mandate Limit. The company affirmed no financial assistance would be provided to grantees for share purchases.